TY - JOUR
T1 - Impact of obesity on treatment of chronic hepatitis C
AU - Charlton, Michael R.
AU - Pockros, Paul J.
AU - Harrison, Stephen A.
PY - 2006/6
Y1 - 2006/6
N2 - Obesity and the metabolic syndrome have hepatic manifestations, including steatosis and progression of fibrosis. In individuals with chronic hepatitis C, obesity is associated with inflammation, insulin resistance, steatosis, progression of fibrosis, and nonresponse to treatment with interferon or peginterferon alpha and ribavirin. Patients with both hepatitis C and obesity-related nonalcoholic fatty liver disease are at greater risk for more advanced liver disease. We review the mechanisms by which obesity may be associated with decreased efficacy of interferon-based therapies in individuals with chronic hepatitis C and the therapeutic strategies that may increase the effectiveness of these therapies in obese individuals.
AB - Obesity and the metabolic syndrome have hepatic manifestations, including steatosis and progression of fibrosis. In individuals with chronic hepatitis C, obesity is associated with inflammation, insulin resistance, steatosis, progression of fibrosis, and nonresponse to treatment with interferon or peginterferon alpha and ribavirin. Patients with both hepatitis C and obesity-related nonalcoholic fatty liver disease are at greater risk for more advanced liver disease. We review the mechanisms by which obesity may be associated with decreased efficacy of interferon-based therapies in individuals with chronic hepatitis C and the therapeutic strategies that may increase the effectiveness of these therapies in obese individuals.
UR - http://www.scopus.com/inward/record.url?scp=33745560465&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745560465&partnerID=8YFLogxK
U2 - 10.1002/hep.21239
DO - 10.1002/hep.21239
M3 - Review article
C2 - 16729327
AN - SCOPUS:33745560465
SN - 0270-9139
VL - 43
SP - 1177
EP - 1186
JO - Hepatology
JF - Hepatology
IS - 6
ER -